Big Pharma: How Obesity Prevention Masks Marketing

Pharmaceutical giants like Eli Lilly and Novo Nordisk are increasingly funding public health campaigns to raise awareness about obesity. While these companies describe the initiatives as educational, regulators in Switzerland and France have launched investigations and issued fines, arguing that such campaigns act as indirect, unauthorized promotion for prescription anti-obesity medications. According to Swissmedic and French regulatory bodies, these initiatives risk blurring the line between medical information and commercial advertising.

Why are pharmaceutical companies funding obesity awareness campaigns?

Large pharmaceutical firms are investing heavily in public health messaging to normalize the discussion around weight management. Eli Lilly, which holds a market capitalization of roughly $1 trillion, launched a campaign in Switzerland featuring the slogan, “Obesity is not your fault.” According to the company, these are “non-promotional, data-driven educational activities” intended to encourage patients to consult healthcare professionals. However, critics note that these campaigns often appear alongside commercial advertisements for fast food, creating a commercial ecosystem where the same companies profit from both the problem and the solution.

How do regulators distinguish between education and advertising?

Regulators maintain that any mention of a disease by a company that produces the primary treatment for that condition can constitute “indirect advertising.” Celine Weber, an attorney specializing in pharmaceutical regulation, notes that the boundary is exceptionally thin. In May 2024, French regulators fined both Eli Lilly and Novo Nordisk, ruling that their communication strategies effectively functioned as prohibited promotion for their anti-obesity drugs. Swissmedic is currently investigating whether similar campaigns in Switzerland violate statutes that require medical information to be balanced, objective, and free from commercial bias.

What are the future trends in pharmaceutical marketing?

The industry is shifting toward “disease awareness” as a core pillar of market expansion. As global obesity rates rise, the demand for injectable treatments like those produced by Novo Nordisk and Eli Lilly continues to climb. Future trends suggest a move toward digital-first campaigns that target specific patient demographics via social media algorithms. According to industry observers, as these companies become more influential, the legal battle over what constitutes “education” versus “promotion” will likely intensify, forcing health authorities to update advertising standards to account for the digital age.

Comparison: Regulatory Stance on Pharma Advertising

Frequently Asked Questions

• Are these awareness campaigns illegal? Not inherently. Companies are allowed to fund health education, but they must remain objective and cannot promote specific prescription drugs.
• Why are regulators investigating these campaigns? Authorities like Swissmedic are concerned that company-sponsored messaging may lead to the inappropriate or excessive use of prescription medications.
• Can companies mention their own products in these ads? In countries where direct-to-consumer advertising is banned, companies cannot promote prescription products. Even mentioning the company name alongside a disease can be flagged as indirect promotion.